全文获取类型
收费全文 | 7398篇 |
免费 | 319篇 |
国内免费 | 92篇 |
专业分类
耳鼻咽喉 | 142篇 |
儿科学 | 165篇 |
妇产科学 | 121篇 |
基础医学 | 1034篇 |
口腔科学 | 101篇 |
临床医学 | 326篇 |
内科学 | 2184篇 |
皮肤病学 | 136篇 |
神经病学 | 459篇 |
特种医学 | 365篇 |
外科学 | 1015篇 |
综合类 | 26篇 |
一般理论 | 4篇 |
预防医学 | 148篇 |
眼科学 | 166篇 |
药学 | 584篇 |
中国医学 | 21篇 |
肿瘤学 | 812篇 |
出版年
2023年 | 37篇 |
2022年 | 19篇 |
2021年 | 93篇 |
2020年 | 64篇 |
2019年 | 77篇 |
2018年 | 122篇 |
2017年 | 104篇 |
2016年 | 171篇 |
2015年 | 169篇 |
2014年 | 211篇 |
2013年 | 302篇 |
2012年 | 465篇 |
2011年 | 506篇 |
2010年 | 294篇 |
2009年 | 259篇 |
2008年 | 484篇 |
2007年 | 530篇 |
2006年 | 541篇 |
2005年 | 528篇 |
2004年 | 510篇 |
2003年 | 531篇 |
2002年 | 565篇 |
2001年 | 77篇 |
2000年 | 62篇 |
1999年 | 89篇 |
1998年 | 125篇 |
1997年 | 83篇 |
1996年 | 68篇 |
1995年 | 71篇 |
1994年 | 68篇 |
1993年 | 92篇 |
1992年 | 65篇 |
1991年 | 53篇 |
1990年 | 42篇 |
1989年 | 37篇 |
1988年 | 29篇 |
1987年 | 22篇 |
1986年 | 27篇 |
1985年 | 28篇 |
1984年 | 20篇 |
1983年 | 22篇 |
1982年 | 26篇 |
1981年 | 24篇 |
1980年 | 15篇 |
1979年 | 7篇 |
1978年 | 14篇 |
1977年 | 8篇 |
1976年 | 9篇 |
1969年 | 7篇 |
1967年 | 6篇 |
排序方式: 共有7809条查询结果,搜索用时 250 毫秒
1.
2.
Hideki Kobara Hirohito Mori Noriko Nishiyama Shintaro Fujihara Keiichi Okano Yasuyuki Suzuki Tsutomu Masaki 《Journal of gastroenterology and hepatology》2019,34(1):22-30
Rescue therapy for gastrointestinal (GI) refractory bleeding, perforation, and fistula has traditionally required surgical interventions owing to the limited performance of conventional endoscopic instruments and techniques. An innovative clipping system, the over‐the‐scope clip (OTSC), may play an important role in rescue therapy. This innovative device is proposed as the final option in endoscopic treatment. The device presents several advantages including having a powerful sewing force for closure of GI defects using a simple mechanism and also having an innovative feature, whereby a large defect and fistula can be sealed using accessory forceps. Consequently, it is able to provide outstanding clinical effects for rescue therapy. This review clarifies the current status and limitations of OTSC according to different indications of GI refractory disease, including refractory bleeding, perforation, fistula, and anastomotic dehiscence. An extensive literature search identified studies reported 10 or more cases in which the OTSC system was applied. A total of 1517 cases described in 30 articles between 2010 and 2018 were retrieved. The clinical success rates and complications were calculated overall and for each indication. The average clinical success rate was 78% (n = 1517) overall, 85% for bleeding (n = 559), 85% (n = 351) for perforation, 52% (n = 388) for fistula, 66% (n = 97) for anastomotic dehiscence, and 95% (n = 122) for other conditions, respectively. The overall and severe OTSC‐associated complications were 1.7% (n = 23) and 0.59% (n = 9), respectively. This review concludes that the OTSC system may serve as a safe and productive device for GI refractory diseases, albeit with limited success for fistula. 相似文献
3.
Kiyotaka Nemoto Tetsuya Shimokawa Masaki Fukunaga Fumio Yamashita Masashi Tamura Hidenaga Yamamori Yuka Yasuda Hirotsugu Azechi Noriko Kudo Yoshiyuki Watanabe Mikio Kido Tsutomu Takahashi Shinsuke Koike Naohiro Okada Yoji Hirano Toshiaki Onitsuka Hidenori Yamasue Michio Suzuki Kiyoto Kasai Ryota Hashimoto Tetsuaki Arai 《Psychiatry and clinical neurosciences》2020,74(1):56-63
4.
5.
6.
7.
Masakazu Tamai Aya Maekawa Noriko Goto Lindun Ge Tsutomu Nishida Hiromi Iwahashi Akinori Yokomi 《The Journal of dermatology》2020,47(10):1175-1178
Individuals infected with the novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) who develop coronavirus disease 2019 (COVID-19) experience many symptoms; however, cutaneous manifestations are relatively rare. The authors encountered three patients with COVID-19 who presented with erythema and suspected viral rash. In all cases, erythema appeared after the onset of the initial symptoms of COVID-19. Erythema was considered to be caused by COVID-19 and not a drug-induced eruption because, in all cases, erythema was relieved merely by external medicine and oral antihistamines, without discontinuing the original medication. The authors’ hospital accepted 69 COVID-19 patients between 22 February 2020 and 31 May 2020 and, of these, three (4.3%) exhibited eruptions, and all cases presented erythema. Except for seven patients who exhibited positive nasopharyngeal swab tests for SARS-CoV-2 RNA but no symptoms, three (4.8%) of the remaining 62 patients exhibited erythema. Although various types of eruptions have been reported in patients with COVID-19, erythema was the only type in our patients. Erythema in the three patients exhibited many similarities to that previously reported in COVID-19 patients, particularly in the manner it appeared and disappeared. For these reasons, these three cases were considered typical examples of erythema in patients with COVID-19. Considering previous studies and the three cases reported here, there is a high probability that SARS-CoV-2 can cause erythema. 相似文献
8.
9.
10.